Although PARP inhibitors changed importantly ovarian cancer treatment landscape, some challenges are still faced, especially in the way of improving PARP inhibitor efficacy in HR-proficient tumors and overcoming PARP resistance in HRD tumors. The gene discussed is PARP1; the disease is ovarian cancer.